Related Experiment Video
Updated: Jun 3, 2026

Flow-sorting and Exome Sequencing of the Reed-Sternberg Cells of Classical Hodgkin Lymphoma
Published on: June 10, 2017
Treatment for relapsed Hodgkin lymphoma: refinement of chemotherapy or targeted treatment?
1Queensland University of Technology, Discipline of Medical Sciences, Faculty of Science and Technology, Brisbane, Australia. sheila.doggrell@qut.edu.au
Abstract:
The prognosis for those with relapsed Hodgkin lymphoma is poor. This evaluation is of two new approaches to the treatment of relapsed Hodgkin lymphoma. First, is a refinement of the chemotherapy for the relapsed condition, which showed that adding SHDCT (sequential high-dose chemotherapy of cyclophosphamine, uromitexane, granulocyte colony-stimulating factor, methotrexate, vincristine, etoposide) did not improve outcome. Second, is new targeted treatment for relapsed Hodgkin disease--brentuximab vedotin, which has an antitubulin agent (monomethylauristatin E) attached to a CD30-specific antibody. This agent gave promising results in a Phase I clinical trial in subjects with relapsed Hodgkin lymphoma. Brentuximab vedotin has produced good initial findings in the treatment of Hodgkin lymphoma and needs to be tested more widely.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers
Tumor Immunotherapy
Treatment Resistant Cancers

